SV2010003464A - Derivados de pirimida utiles para el tratamiento de condiciones inflamatorias o alergicas - Google Patents
Derivados de pirimida utiles para el tratamiento de condiciones inflamatorias o alergicasInfo
- Publication number
- SV2010003464A SV2010003464A SV2010003464A SV2010003464A SV2010003464A SV 2010003464 A SV2010003464 A SV 2010003464A SV 2010003464 A SV2010003464 A SV 2010003464A SV 2010003464 A SV2010003464 A SV 2010003464A SV 2010003464 A SV2010003464 A SV 2010003464A
- Authority
- SV
- El Salvador
- Prior art keywords
- treatment
- pyrimidate
- inflammatory
- derivatives
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UN COMPUESTO DE LA FÓRMULA (I): (VER FORMULA); O UNA SAL, ADECUADAMENTE UNA SAL FARMACÉUTICAMENTE ACEPTABLE, O SOLVATO DEL MISMO, EN DONDE LOS GRUPOS R1, R2, AR', A Y B SON DEFINIDOS EN LA DESCRIPCIÓN, A COMPOSICIONES Y USO DE LOS COMPUESTOS EN EL TRATAMIENTO DE ENFERMEDADES MEJORADAS POR LA INHIBICIÓN DE FOSFATIDILINOSITOL 3-CINASA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07113237 | 2007-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2010003464A true SV2010003464A (es) | 2010-05-21 |
Family
ID=38942282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2010003464A SV2010003464A (es) | 2007-07-26 | 2010-01-26 | Derivados de pirimida utiles para el tratamiento de condiciones inflamatorias o alergicas |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP2173722B1 (es) |
JP (1) | JP5485884B2 (es) |
KR (1) | KR20100025006A (es) |
CN (1) | CN101765591B (es) |
AR (1) | AR067869A1 (es) |
AU (1) | AU2008278966B2 (es) |
BR (1) | BRPI0813629A2 (es) |
CA (1) | CA2694275A1 (es) |
CL (1) | CL2008002185A1 (es) |
CO (1) | CO6290670A2 (es) |
CR (1) | CR11208A (es) |
EA (1) | EA201000104A1 (es) |
EC (1) | ECSP109900A (es) |
ES (1) | ES2394126T3 (es) |
MA (1) | MA31594B1 (es) |
MX (1) | MX2010001020A (es) |
PE (1) | PE20090880A1 (es) |
SV (1) | SV2010003464A (es) |
TN (1) | TN2010000038A1 (es) |
TW (1) | TW200909426A (es) |
WO (1) | WO2009013348A2 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8268834B2 (en) * | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
GB0815947D0 (en) * | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
MX2011009796A (es) | 2009-03-20 | 2011-12-14 | Amgen Inc | Inhibidores de la cinasa pi3. |
UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
JP4967004B2 (ja) * | 2009-09-14 | 2012-07-04 | 東京エレクトロン株式会社 | レジスト塗布現像装置およびレジスト塗布現像方法 |
TN2016000270A1 (en) | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
EP3094326A4 (en) | 2014-01-14 | 2017-07-26 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
US10112926B2 (en) | 2014-04-24 | 2018-10-30 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
BR112016024533A8 (pt) | 2014-04-24 | 2021-03-30 | Novartis Ag | derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas |
ES2667424T3 (es) | 2014-04-24 | 2018-05-10 | Novartis Ag | Derivados de pirazina como inhibidores de fosfatidil-inositol-3-quinasa |
WO2019126733A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
WO2019226213A2 (en) | 2018-03-08 | 2019-11-28 | Incyte Corporation | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998024782A2 (en) * | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidine compounds and their use |
ES2240449T3 (es) * | 2000-02-25 | 2005-10-16 | F. Hoffmann-La Roche Ag | Moduladores receptores de adenosina. |
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
AU2002310187A1 (en) * | 2001-05-30 | 2002-12-09 | Lg Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
AUPR688101A0 (en) * | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
TWI330183B (es) * | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
AU2002950853A0 (en) * | 2002-08-19 | 2002-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compound and pharmaceutical use thereof |
WO2004029204A2 (en) * | 2002-09-27 | 2004-04-08 | Merck & Co., Inc. | Substituted pyrimidines |
CN1735607B (zh) * | 2002-11-21 | 2010-06-09 | 诺华疫苗和诊断公司 | 2,4,6-三取代的嘧啶作为磷脂酰肌醇(pi)3-激酶抑制剂及其在治疗癌症中的应用 |
KR101052482B1 (ko) * | 2002-11-21 | 2011-07-28 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 포스포티딜이노시톨(pi) 3-키나제 억제제인 2,4,6-삼치환피리미딘 및 암의 치료에서 이들의 사용 |
CN103265477B (zh) * | 2003-02-26 | 2017-01-11 | 苏根公司 | 作为蛋白激酶抑制剂的氨基杂芳基化合物 |
SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
CN1816370A (zh) * | 2003-06-30 | 2006-08-09 | 麦克公司 | 用作雄激素受体调节剂的17-乙酰氨基-4-氮杂甾族化合物衍生物 |
ES2229928B1 (es) * | 2003-10-02 | 2006-07-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirimidin-2-amina. |
AU2005269386A1 (en) * | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
SE0402735D0 (sv) * | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
EP1858882A1 (en) * | 2005-03-10 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives for treatment of hyperproliferative disorders |
DE602007004092D1 (de) * | 2006-03-22 | 2010-02-11 | Vertex Pharma | C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen |
GB0608820D0 (en) * | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
GB0610242D0 (en) * | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
ES2379830T3 (es) * | 2006-07-28 | 2012-05-04 | Novartis Ag | Quinazolinas sustituidas en 2,4- como inhibidores de quinasa lipídica |
CA2662074A1 (en) * | 2006-08-30 | 2008-03-06 | Cellzome Limited | Triazole derivatives as kinase inhibitors |
CL2008001933A1 (es) * | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
-
2008
- 2008-07-24 WO PCT/EP2008/059748 patent/WO2009013348A2/en active Application Filing
- 2008-07-24 EA EA201000104A patent/EA201000104A1/ru unknown
- 2008-07-24 KR KR1020107001657A patent/KR20100025006A/ko active IP Right Grant
- 2008-07-24 JP JP2010517408A patent/JP5485884B2/ja active Active
- 2008-07-24 AU AU2008278966A patent/AU2008278966B2/en not_active Expired - Fee Related
- 2008-07-24 EP EP08775347A patent/EP2173722B1/en active Active
- 2008-07-24 ES ES08775347T patent/ES2394126T3/es active Active
- 2008-07-24 MX MX2010001020A patent/MX2010001020A/es not_active Application Discontinuation
- 2008-07-24 CA CA2694275A patent/CA2694275A1/en not_active Abandoned
- 2008-07-24 CN CN2008801002897A patent/CN101765591B/zh active Active
- 2008-07-24 BR BRPI0813629A patent/BRPI0813629A2/pt not_active IP Right Cessation
- 2008-07-24 PE PE2008001259A patent/PE20090880A1/es not_active Application Discontinuation
- 2008-07-25 CL CL2008002185A patent/CL2008002185A1/es unknown
- 2008-07-25 TW TW097128507A patent/TW200909426A/zh unknown
- 2008-07-28 AR ARP080103260A patent/AR067869A1/es not_active Application Discontinuation
-
2010
- 2010-01-08 CR CR11208A patent/CR11208A/es not_active Application Discontinuation
- 2010-01-22 TN TNP2010000038A patent/TN2010000038A1/fr unknown
- 2010-01-25 CO CO10007032A patent/CO6290670A2/es not_active Application Discontinuation
- 2010-01-26 SV SV2010003464A patent/SV2010003464A/es not_active Application Discontinuation
- 2010-01-26 EC EC2010009900A patent/ECSP109900A/es unknown
- 2010-02-05 MA MA32591A patent/MA31594B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
MA31594B1 (fr) | 2010-08-02 |
EP2173722B1 (en) | 2012-08-29 |
CN101765591A (zh) | 2010-06-30 |
WO2009013348A3 (en) | 2009-07-23 |
MX2010001020A (es) | 2010-03-01 |
AU2008278966A1 (en) | 2009-01-29 |
CA2694275A1 (en) | 2009-01-29 |
AU2008278966B2 (en) | 2012-02-23 |
WO2009013348A2 (en) | 2009-01-29 |
KR20100025006A (ko) | 2010-03-08 |
JP2010534634A (ja) | 2010-11-11 |
ES2394126T3 (es) | 2013-01-22 |
PE20090880A1 (es) | 2009-08-06 |
AR067869A1 (es) | 2009-10-28 |
CO6290670A2 (es) | 2011-06-20 |
TN2010000038A1 (en) | 2011-09-26 |
ECSP109900A (es) | 2010-02-26 |
CL2008002185A1 (es) | 2009-02-20 |
JP5485884B2 (ja) | 2014-05-07 |
EA201000104A1 (ru) | 2010-08-30 |
CN101765591B (zh) | 2013-11-27 |
EP2173722A2 (en) | 2010-04-14 |
TW200909426A (en) | 2009-03-01 |
BRPI0813629A2 (pt) | 2018-07-10 |
CR11208A (es) | 2010-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2010003464A (es) | Derivados de pirimida utiles para el tratamiento de condiciones inflamatorias o alergicas | |
ECSP10010556A (es) | Piridinas y pirazinas como inhibidores de pi3k | |
UY32490A (es) | Inhibidores de beta-secretasa | |
SV2010003598A (es) | Derivados de tiazol usados como inhibidores de pi 3-cinasa | |
AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
CL2011000504A1 (es) | Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer. | |
ECSP11011560A (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
PA8785401A1 (es) | Derivados de bencimidazol | |
ECSP11010754A (es) | Derivados de triazol útiles para el tratamiento de enfermedades | |
EA200900924A1 (ru) | Циклизованные производные как ингибиторы eg-5 | |
AR062394A1 (es) | Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis | |
AR067770A1 (es) | Derivados de tiazol y ditiazol para el tratamiento de diabetes | |
CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
CO6270285A2 (es) | Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida | |
AR062390A1 (es) | Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas | |
AR073117A1 (es) | Derivado de aminometil-fenil-piperidin-1-il-indolil-metanona, inhibidores de la triptasa de mastocitos, composiciones farmaceuticas que lo contienen, metodo de preparacion, compuestos intermediarios y uso del compuesto en el tratamiento de procesos inflamatorios. | |
ECSP099506A (es) | Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos | |
MX2008016358A (es) | Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3. | |
AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
ECSP099328A (es) | Análogos de pirazol | |
AR088735A1 (es) | Compuestos de tienopirimidina que son inhibidores de canal de potasio | |
ECSP088237A (es) | Derivados de quinolina y uso como agentes antitumor | |
CU20100014A7 (es) | Derivados de pirimidina útiles para el tratamiento de enfermedades inflamatorias o alérgicas | |
CU20100179A7 (es) | Piridinas y pirazinas como inhibidores de p13k | |
ATE505189T1 (de) | Benztropinamin-analoge als dopamin-aufnahmehemmer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Lapse |